VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [RNA-Seq 3]
Ontology highlight
ABSTRACT: To investigate the function of VGLL1 in breast cancer and its role in the resistance to endocrine therapies we generated stable MCF7 cells overexpressing VGLL1 using CRISPR/Cas9 Synergistic Activation Mediator (SAM) method (MCF7 ActCas9-VGLL1 cells). MCF7 ActCas9-VGLL1 cells were also cultured in the presence of fulvestrant 100nmM or 1µM to develop fulvestrant resistant cells (MCF7 ActCas9-VGLL1-FULVR) and RNA-seq was performed in the different cell lines.
ORGANISM(S): Homo sapiens
PROVIDER: GSE216528 | GEO | 2023/12/05
REPOSITORIES: GEO
ACCESS DATA